Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Hepatic Encephalopathy

Hepatic Encephalopathy

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Hepatic Encephalopathy

13 trials tracked for Hepatic Encephalopathy: 4 in phase 3 or 4 and 3 with published results. The most-cited published study has 1274 citations.

13Trials tracked
4Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 1 Phase 3 3 Phase 2 4 Other / NA 5
  1. Phase 3 A 6-month Efficacy, Safety, and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy Completed · 1,274 cited
  2. Phase 3 Safety and Tolerability Study of Rifaximin in Participants With a History of Hepatic Encephalopathy Completed · 207 cited
  3. Phase 4 The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy Completed · 45 cited
  4. Phase 3 N-acetylcysteine in Non-Acetaminophen Pediatric Acute Liver Failure Completed
  5. Phase 2 FMT in Cirrhosis and Hepatic Encephalopathy Completed
  6. Phase 2 Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE) Completed
Show 7 more trials
  1. Phase 2 A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy Completed
  2. Phase 2 VE303 for Treatment of Hepatic Encephalopathy (HE) Completed
  3. N/A Rifaximin in Minimal Hepatic Encephalopathy Completed
  4. N/A Effect of Rifaximine on Sleep Disorders in Patients Suffering From Hepatic Encephalopathy Completed
  5. N/A Efficacy Study of Polyethylene Glycol 3350-electrolyte Solution (GoLYTELY®) Versus Lactulose in Patients With Hepatic Encephalopathy. Completed
  6. N/A The BRAINFOOD Trial to Prevent Recurrent Hepatic Encephalopathy. Completed
  7. N/A A Retrospective, Open-label, Uncontrolled Cohort Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) [The RETRO Study] Completed

Showing the 13 most-cited and recently-updated of 13 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Hepatic Encephalopathy: what the trials found

Rifaximin has been shown to significantly reduce the number of participants reporting a first breakthrough hepatic encephalopathy (HE) episode 1. Additionally, Rifaximin was associated with a significant increase in the time to the first breakthrough overt HE episode 2.

Clinical assessments using the Conn Score showed a reduction from baseline following Rifaximin administration 3. Evidence also indicates that Rifaximin is associated with specific scores regarding total sickness impact 10.

N-acetylcysteine was evaluated for its effect on spontaneous recovery, showing a statistically significant difference in outcomes compared to control 4. However, N-acetylcysteine did not show statistically significant results regarding survival or the cumulative percent incidence of transplantation within one year 4.

Recent results — preliminary, needs further review

  • Fecal microbial transplant capsules showed changes in Psychometric Hepatic Encephalopathy Score performance (not yet corroborated).
  • HPN-100 was associated with a lower proportion of subjects exhibiting an HE episode and fewer total HE events compared to placebo (not yet corroborated).
  • Ornithine phenylacetate was evaluated regarding the percentage of participants in each HE stage (not yet corroborated).
  • Polyethylene glycol 3350-electrolyte solution was assessed for improvements in HE grade at 24 hours (not yet corroborated).

For the clinician treating this condition

  • Rifaximin is associated with a reduction in breakthrough HE episodes and an increased time to the first overt HE episode.
  • N-acetylcysteine shows evidence of association with improved spontaneous recovery, though it did not significantly impact survival rates or transplantation timing.
  • Rifaximin administration is linked to measurable changes in Conn scores and sickness impact profiles.

AI synthesis of 5 cited trials, updated Aug 2, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.